Optical Biometry Derived Axial Length Measurements Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema.

Détails

ID Serval
serval:BIB_0FBA462D5C79
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Optical Biometry Derived Axial Length Measurements Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema.
Périodique
Seminars in ophthalmology
Auteur⸱e⸱s
Kymionis G.D., Giarmoukakis A., Apostolidi I.K., Blazaki S.V., Tsoulnaras K.I., Moschandrea J., Panagopoulou S., Tsilimbaris M.K.
ISSN
1744-5205 (Electronic)
ISSN-L
0882-0538
Statut éditorial
Publié
Date de publication
2018
Peer-reviewed
Oui
Volume
33
Numéro
4
Pages
488-491
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To evaluate axial length (AL) alterations in patients with macular disease over the course of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment.
In this prospective, comparative study, 33 patients with macular edema underwent unilaterally intravitreal anti-VEGF therapy and were followed for two months; the contralateral eyes were considered as controls. Central retinal thickness (CRT) was measured with spectral-domain optical coherence tomography and AL with an IOL-Master optical biometer.
CRT of the treated eyes decreased by 35.33 ± 65.59 μm (range, -222.00-67 μm), while AL increased by 0.008 ± 0.062 mm (range, -0.11-0.18 mm). CRT of the control group decreased by 9.82 ± 65.40 μm (range, -203-182 μm), and AL increased by 0.011 ± 0.129 mm (range, -0.20-0.67 mm). No significant correlation was detected between CRT and AL parameters (rhos=0.026, P=0.882).
Anti-VEGF administration has no significant impact on optical biometry-derived AL measurements.
Mots-clé
Aged, Angiogenesis Inhibitors/administration & dosage, Axial Length, Eye/diagnostic imaging, Biometry/methods, Female, Fluorescein Angiography, Fundus Oculi, Humans, Intravitreal Injections, Macula Lutea/pathology, Macular Edema/diagnosis, Macular Edema/drug therapy, Macular Edema/physiopathology, Male, Prospective Studies, Ranibizumab/administration & dosage, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Visual Acuity, Anti-vascular endothelial growth factor, IOL Master biometry, axial length, central retinal thickness, macular edema
Pubmed
Web of science
Création de la notice
28/04/2017 10:10
Dernière modification de la notice
20/08/2019 13:36
Données d'usage